A recent study published in JAMA Network Open investigates the impact of GLP-1 receptor agonists (GLP-1RAs) on the risk of hematologic cancers in patients with type 2 diabetes (T2D). Previous research has linked T2D and obesity to an increased risk of various cancers, including blood-related malignancies. While GLP-1RAs have been associated with reduced risks of solid tumors, their effects on hematologic cancers remained unexplored.

      This retrospective cohort study utilized data from the TriNetX network, encompassing electronic health records from approximately one-quarter of the U.S. population. Researchers analyzed patients diagnosed with T2D who were prescribed GLP-1RAs, insulin, or metformin between April 30, 2005, and October 31, 2023.

      After propensity matching for various factors, including demographics, BMI, diabetic complications, and prior cancer screenings, two comparative analyses were conducted. When compared with insulin users, GLP-1RA treatment was associated with a markedly lower risk of multiple blood cancers, including myeloid leukemia (hazard ratio [HR], 0.39; 95% CI, 0.25-0.60; P < .001), lymphoid leukemia (HR, 0.45; 95% CI, 0.30-0.68; P < .001), and non-Hodgkin lymphoma (HR, 0.42; 95% CI, 0.30-0.58; P < .001). GLP-1RA demonstrated a reduced risk for myelodysplastic syndromes (HR, 0.19; 95% CI, 0.11-0.35; P < .001) and myeloproliferative neoplasms (HR, 0.50; 95% CI, 0.41-0.61; P < .001) compared with insulin therapy. Additionally, GLP-1RA showed a lower risk for myelodysplastic syndromes (HR, 0.61; 95% CI, 0.42-0.89; P = .01) and myeloproliferative neoplasms (HR, 0.67; 95% CI, 0.52-0.87; P = .002) than metformin. Across all hematologic cancers, GLP-1RA use was associated with 54% lower risk than insulin therapy, suggesting potential protective effects against blood cancer development.

      The study suggests that the protective effect of GLP-1RAs against hematologic cancer may be attributed to their role in weight loss and immune modulation. These drugs are known to reduce inflammation and affect cytokines involved in hematopoiesis, which could help mitigate cancer risk.

Read More